{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:37Z","timestamp":1790821537660,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03047-w","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:22:50Z","timestamp":1732170170000},"page":"395-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase\u00a04 and PROCLAIM Phase\u00a03 Studies with a Focus on Older Patients"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-3480","authenticated-orcid":false,"given":"Yang","family":"Mao-Draayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-0335","authenticated-orcid":false,"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3409-8731","authenticated-orcid":false,"given":"Konstantin","family":"Balashov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-3937","authenticated-orcid":false,"given":"Erin E.","family":"Longbrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-0981","authenticated-orcid":false,"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-7836","authenticated-orcid":false,"given":"Nicholas","family":"Everage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2205-4233","authenticated-orcid":false,"given":"Ivan","family":"Bo\u017ein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Mokliatchouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6289-0562","authenticated-orcid":false,"given":"Eris","family":"Bame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"9313","key":"3047_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221\u201331.","journal-title":"Lancet"},{"issue":"1","key":"3047_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2011-300616","volume":"83","author":"E Kingwell","year":"2012","unstructured":"Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012;83(1):61\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"3047_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/PPA.S142373","volume":"11","author":"G Lee Mortensen","year":"2017","unstructured":"Lee Mortensen G, Rasmussen PV. The impact of quality of life on treatment preferences in multiple sclerosis patients. Patient Prefer Adherence. 2017;11:1789\u201396.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"3047_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","volume":"15","author":"CB Vaughn","year":"2019","unstructured":"Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol. 2019;15(6):329\u201342.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"3047_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","volume":"74","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74(6):465\u201371.","journal-title":"Neurology"},{"issue":"8","key":"3047_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","volume":"17","author":"E Grebenciucova","year":"2017","unstructured":"Grebenciucova E, Berger JR. Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep. 2017;17(8):61.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"13","key":"3047_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/1352458516630396","volume":"22","author":"A Scalfari","year":"2016","unstructured":"Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler. 2016;22(13):1750\u20138.","journal-title":"Mult Scler"},{"issue":"12","key":"3047_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J, Devonshire V, Neurologists UC. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"3047_CR10","doi-asserted-by":"publisher","DOI":"10.4110\/in.2019.19.e37","volume":"19","author":"SJ Oh","year":"2019","unstructured":"Oh SJ, Lee JK, Shin OS. Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity. Immune Netw. 2019;19(6):e37.","journal-title":"Immune Netw"},{"issue":"5","key":"3047_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ni.2588","volume":"14","author":"JJ Goronzy","year":"2013","unstructured":"Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428\u201336.","journal-title":"Nat Immunol"},{"issue":"10","key":"3047_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00018-012-0970-0","volume":"69","author":"JJ Goronzy","year":"2012","unstructured":"Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615\u201323.","journal-title":"Cell Mol Life Sci"},{"key":"3047_CR13","unstructured":"Balusha AAK, Morrow SA. Multiple sclerosis in people over age 55. Pract Neurol. 2021:41\u201343."},{"issue":"7","key":"3047_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase\u00a04, non-inferiority trial. Lancet Neurol. 2023;22(7):568\u201377.","journal-title":"Lancet Neurol"},{"key":"3047_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"3047_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40120-022-00413-0","volume":"12","author":"B Lager","year":"2022","unstructured":"Lager B, Liseno J, Bozin I, et al. Real-world analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2022;12(1):145\u201359.","journal-title":"Neurol Ther"},{"issue":"12","key":"3047_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase\u00a03 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"12","key":"3047_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase\u00a03 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"5","key":"3047_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13\u00a0years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022;28(5):801\u201316.","journal-title":"Mult Scler"},{"issue":"3","key":"3047_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220\u20139.","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"3047_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/1352458518775550","volume":"24","author":"EA Mills","year":"2018","unstructured":"Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler. 2018;24(8):1014\u201322.","journal-title":"Mult Scler"},{"issue":"4","key":"3047_CR22","first-page":"205521732211324","volume":"8","author":"J Lyons","year":"2022","unstructured":"Lyons J, Hughes R, McCarthy K, et al. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. Mult Scler J Exp Transl Clin. 2022;8(4):20552173221132468.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"15","key":"3047_CR23","doi-asserted-by":"publisher","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","volume":"92","author":"D Mehta","year":"2019","unstructured":"Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92(15):e1724\u201338.","journal-title":"Neurology"},{"issue":"6","key":"3047_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1352458520937282","volume":"27","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2021;27(6):883\u201394.","journal-title":"Mult Scler"},{"key":"3047_CR25","unstructured":"Repovic PRD, Cohan SL, Mao-Draayer Y, Xiong K, Borowski J, Avila-Carey R. Efficacy of delayed-release dimethyl fumarate in patients \u2265 55\u00a0years enrolled in the RESPOND study In: Americas Committee for Treatment and Research in Multiple Sclerosis - 2020 Forum. West Palm Beach, FL. 2020."},{"issue":"6","key":"3047_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.7224\/1537-2073.2020-109","volume":"23","author":"A Salter","year":"2021","unstructured":"Salter A, Lancia S, Cutter G, et al. Characterizing long-term disability progression and employment in NARCOMS registry participants with multiple sclerosis taking dimethyl fumarate. Int J MS Care. 2021;23(6):239\u201344.","journal-title":"Int J MS Care"},{"issue":"1","key":"3047_CR27","first-page":"205521732110698","volume":"8","author":"CM Hersh","year":"2022","unstructured":"Hersh CM, Altincatal A, Belviso N, et al. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Mult Scler J Exp Transl Clin. 2022;8(1):20552173211069852.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3047_CR28","doi-asserted-by":"publisher","first-page":"175628641879640","DOI":"10.1177\/1756286418796404","volume":"11","author":"E D'Amico","year":"2018","unstructured":"D\u2019Amico E, Zanghi A, Callari G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord. 2018;11:1756286418796404.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"3047_CR29","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/acn3.51111","volume":"7","author":"BL Vollmer","year":"2020","unstructured":"Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020;7(9):1466\u201376.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"3047_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40120-020-00192-6","volume":"9","author":"A Chinea","year":"2020","unstructured":"Chinea A, Amezcua L, Vargas W, et al. Real-world safety and effectiveness of dimethyl fumarate in Hispanic or Latino patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):495\u2013504.","journal-title":"Neurol Ther"},{"issue":"2","key":"3047_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","volume":"9","author":"MJ Williams","year":"2020","unstructured":"Williams MJ, Amezcua L, Okai A, et al. Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):483\u201393.","journal-title":"Neurol Ther"},{"key":"3047_CR32","doi-asserted-by":"crossref","unstructured":"Williams MJ, Amezcua L, Chinea A, et al. Real-world safety and effectiveness after 5\u00a0years of dimethyl fumarate treatment in black and hispanic patients with multiple sclerosis in ESTEEM. Neurol Ther. 2023;12(5):1669\u201382.","DOI":"10.1007\/s40120-023-00517-1"},{"issue":"2","key":"3047_CR33","first-page":"205521732091861","volume":"6","author":"G Buckle","year":"2020","unstructured":"Buckle G, Bandari D, Greenstein J, et al. Weinstock-Guttman B, Thrower B, et al. Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6(2):2055217320918619.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3047_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100470","volume":"22","author":"JS Brand","year":"2022","unstructured":"Brand JS, Smith KA, Piehl F, Olsson T, Montgomery S. Risk of serious infections in multiple sclerosis patients by disease course and disability status: results from a Swedish register-based study. Brain Behav Immun Health. 2022;22: 100470.","journal-title":"Brain Behav Immun Health"},{"key":"3047_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116673","volume":"175","author":"A Shadab","year":"2024","unstructured":"Shadab A, Abbasi-Kolli M, Saharkhiz M, Ahadi SH, Shokouhi B, Nahand JS. The interplay between mitochondrial dysfunction and NLRP3 inflammasome in multiple sclerosis: therapeutic implications and animal model studies. Biomed Pharmacother. 2024;175:116673.","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"3047_CR36","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1016\/j.neuron.2022.06.023","volume":"110","author":"VW Yong","year":"2022","unstructured":"Yong VW. Microglia in multiple sclerosis: protectors turn destroyers. Neuron. 2022;110(21):3534\u201348.","journal-title":"Neuron"},{"issue":"11","key":"3047_CR37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.tins.2019.09.004","volume":"42","author":"A Sierra","year":"2019","unstructured":"Sierra A, Paolicelli RC, Kettenmann H. Cien anos de microglia: milestones in a century of microglial research. Trends Neurosci. 2019;42(11):778\u201392.","journal-title":"Trends Neurosci"},{"key":"3047_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.894298","volume":"15","author":"Y Cui","year":"2022","unstructured":"Cui Y, Yu H, Bu Z, Wen L, Yan L, Feng J. Focus on the role of the NLRP3 inflammasome in multiple sclerosis: pathogenesis, diagnosis, and therapeutics. Front Mol Neurosci. 2022;15:894298.","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"3047_CR39","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315.","journal-title":"Neurology"},{"key":"3047_CR40","doi-asserted-by":"crossref","unstructured":"Saraste M, Bezukladova S, Matilainen M, et al. High serum neurofilament associates with diffuse white matter damage in MS. Neurol Neuroimmunol Neuroinflamm 2021;8(1):e926.","DOI":"10.1212\/NXI.0000000000000926"},{"issue":"1","key":"3047_CR41","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","volume":"10","author":"S Thebault","year":"2020","unstructured":"Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10(1):10381.","journal-title":"Sci Rep"},{"issue":"1","key":"3047_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11(1):812.","journal-title":"Nat Commun"},{"issue":"12","key":"3047_CR43","first-page":"1324","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry. 2019;90(12):1324\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03047-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:48Z","timestamp":1738235028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03047-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03047-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yang Mao-Draayer: consulting fees from Biogen, Celgene, EMD Serono, Genzyme, Novartis, and Roche-Genentech; contracted research for Biogen, Chugai, NIAID Autoimmune Center of Excellence UM1-AI110557, NIH NINDS R01-NS080821, Novartis, and Sanofi-Genzyme; speaker bureaus for Biogen and Teva. Amit Bar-Or: speaker\/consulting fees and\/or grant support from Atara Biotherapeutics, Biogen, Celgene\/Receptos, Genentech\/Roche, GlaxoSmithKline, Medimmune, Merck\/EMD Serono, Novartis, and Sanofi-Genzyme. Konstantin Balashov: grant\/research support from Biogen; consultant for Genentech\/Roche. John Foley: nothing to disclose. Kyle Smoot: received research support from AbbVie, Biogen, EMD Serono, Genentech, IMS Health, MedDay, and Novartis; and consulting fees from Biogen, Celgene, EMD Serono, Genzyme, Genentech, and Janssen. Erin E. Longbrake: consulting fees from Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, NGM Bio, and TG Therapeutics; research support from CTSA\u00a0Grant\u00a0Number KL2 TR001862, Nancy Davis Center Without Walls, and NIH NINDS K23-NS10762. Derrick Robertson: received grant support from Anokion, Atara Biotherapeutics, Biogen, CorEvitas, EMD Serono, Genentech, GW Pharmaceuticals, Janssen, Novartis, PCORI, PRIME CME, Sanofi, and TG Therapeutics; has received consulting fees from Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon, Janssen, Mallinckrodt, Novartis, Sanofi, and TG Therapeutics; has received honoraria or speaker fees from Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Horizon, Janssen, PRIME CME, Sanofi and TG Therapeutics. Fabrizio Giuliani: speaker\/consulting fees and\/or grant support from Biogen, Genentech\/Roche, Merck\/EMD Serono, Novartis, and Sanofi-Genzyme. Jason P. Mendoza, James B. Lewin, Nicholas Everage, Ivan Bo\u017ein, Jennifer Lyons, Oksana Mokliatchouk, Eris Bame: employees of and may hold stock in Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ESTEEM and PROCLAIM studies were conducted in accordance with the International Conference on Harmonization Guidelines on Good Clinical Practice, the ethical principles outlined in the Declaration of Helsinki, and all applicable local laws and regulations. ESTEEM was approved by local ethics committees at each of the 393 sites, which were overseen by the ESTEEM Study Contract Research Organization ethics committee. PROCLAIM investigators were required to obtain approval of the protocol, informed consent form, and other required study documents from the local ethics committee, overseen by the PROCLAIM Study Contract Research Organization. In both studies, written assent and consent forms were obtained from each patient or their parent or legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}